Yinchen Mutong Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a botanical active pharmaceutical ingredient prepared from the dried herb of Yinchen and the dried stem of Mutong, processed by de-dusting, controlled milling, and moisture adjustment for pharmaceutical formulation. It is supplied as a fine powder for downstream manufacture into seven specified dosage forms; it is not a finished medicated feed, a sterile injection, or a diluted premix. The product is controlled by a release specification covering botanical identity, loss on drying, total ash, heavy metals, pesticide residues, mycotoxin screening where required, and microbial quality. A single public model designator is not present in the current technical literature; batch-specific model suffixes assigned by the manufacturer are used to distinguish particle-size and endotoxin-controlled grades for solid oral, liquid oral, and injectable processing. The receiving formulator should request the exact grade designation and batch release certificate before equipment qualification or stability studies.

The dual botanical nature of the powder creates a more complex control problem than a single-herb extract. It cannot be standardized to one marker alone; a chromatographic fingerprint or multi-marker assay is required. This is one of the primary differences from purified or single-component APIs, where identity and potency can be verified by a single peak. It also differentiates this product from feed-grade herbal powders that do not require pharmaceutical release testing.

The botanical material is typically dried in a belt dryer or tray dryer to a defined moisture endpoint before milling. The mill type—whether a pin mill, hammer mill, or classifying mill—affects the width of the particle-size distribution. A pin mill with a classifier is often preferred for injectable-grade lots because it produces a narrow particle-size cut and reduces the coarse fibrous fraction that can block downstream filters. The milled powder is then sieved and blended in a ribbon blender to ensure homogeneity of the two botanical components. Because heat generated during milling may soften cuticular waxes, the milling chamber should be kept below 40 °C for heat-sensitive botanical APIs. These are general processing controls; the supplier's process validation report should confirm the specific milling and blending parameters.

What Distinguishes an API-Grade Two-Botanical Powder from a Crude Herbal Premix?

In low-shear feed mixing, a crude botanical powder is commonly accepted with a broad particle-size distribution and a microbial count governed by feed hygiene rather than pharmacopoeial limits. The API-grade material differs in three respects: it is subjected to controlled comminution with a defined sieve cut, it is dried to a residual moisture range compatible with capsule filling and direct compression, and it is released against pharmacopoeial test methods. These controls do not guarantee that all lots are identical; batch-to-batch variability of botanical secondary metabolites remains a known limitation. A formulator should therefore fix the ratio of the two plant species in the product specification and confirm marker bands by chromatographic fingerprinting before scale-up.

Table 1 summarizes the test matrix that separates this product from feed-grade botanical powders.

The table is not a finished-product specification; it is a control set applied to the API. Absence of a harmonized monograph for the two-herb combination means the manufacturer should maintain a validated in-house method for botanical identity and marker content. Published data for this specific configuration is limited; therefore, release limits should be justified by stability and process capability data rather than by transposing limits from single-herb monographs.

Particle Size, Bulk Density, and Flow Function Across the Seven Dosage Platforms

Because the powder is not a pre-solubilized extract, its solid-state behavior determines whether a batch can be transferred among tablets, capsules, powders, granules, premix, and solutions without re-milling. Direct compression on a rotary press with a force feeder requires adequate flow; if the powder is too cohesive, die filling becomes non-uniform and weight variability increases. A particle-size target of 80 µm to 150 µm D90 is commonly used for botanical direct compression, but the exact D90 should be set after pilot compaction. For capsule filling on dosator-type machines, bulk density and flow are more important than simple particle size. For premix and granule manufacture, sieve fraction and dusting tendency govern blend uniformity with feed carriers.

Table 2 summarizes process-critical properties for the seven dosage platforms.

In direct compression, the main failure mode is lamination caused by elastic recovery of fibrous vascular tissue after compaction. This is controlled by adding plastic diluents or by wet granulation. A residual moisture range of 3.0% to 5.0% w/w is often used for botanical powders to reduce sticking on B-tooling, but moisture below 2.0% w/w may increase static charging and segregation in low-shear tumblers. These values are process guidelines, not release specifications; the final limits must be proven by process capability.

On a production-scale rotary tablet press equipped with a force feeder and B-tooling, the fibrous fraction of the powder may increase ejection force. If magnesium stearate is raised beyond 2.0% w/w to reduce ejection force, dissolution may slow, particularly for poorly water-soluble botanical constituents. Wet granulation with povidone K30 binder solution at 5% w/w solids often reduces capping, but the granule moisture must be reduced to a final value below 4.0% w/w before compression. These are standard responses for botanical APIs and should be confirmed on a pilot batch. For capsules, dosator-type machines require a minimum powder column height that is affected by tap density; a tap density below 0.45 g/mL may require forced filling or pre-compaction. The tap density limit should be set after the capsule machine type and speed are fixed.

For premix and powder use, segregation is governed by particle-size match with the feed carrier. If the carrier particle size is larger than 500 µm, the API may sift downward in the feed bin; a pre-blend with a carrier of similar size is therefore required. Direct addition to pelleted feed without a pre-mix step may cause blend uniformity to fail the CV ≤ 5.0% criterion typical of medicated feed tests. Uniformity is measured by USP <905> or the equivalent current pharmacopoeial uniformity method, and the manufacturer must validate blend uniformity on the actual mixer.

When Aqueous Solution or Injectable Formulation Is Attempted, Which Risk Controls Apply?

Typically, the limiting test for injectable development is not chemical potency but filterability and bacterial endotoxin burden. The botanical origin of the powder introduces natural endotoxin loading that must be reduced or shown to be below the aqueous parenteral threshold. Aqueous extraction may dissolve polysaccharides and tannins that form colloidal haze after cooling. Filtration through a 0.45 µm prefilter before a 0.22 µm sterilizing membrane is common, but filter blocking can occur if extraction temperature or pH is not controlled. If the solution is heat-sterilized at 121 °C for 15 min, precipitation or color change must be evaluated; aseptic filtration is preferred when thermal degradation markers exceed the specification.

For oral solutions, the microbial quality requirement is less stringent than for parenterals, but the powder must still not raise the finished product total aerobic count beyond its specification. The API is tested against Ph. Eur. 2.6.12 and 2.6.13; for injectable-grade lots, bacterial endotoxins are tested by Ph. Eur. 2.6.14. Sub-visible particulate matter for injectable solutions is assessed after final filtration by Ph. Eur. 2.9.19. A depyrogenation step such as dry heat treatment should only be introduced after demonstrating that secondary metabolites are not degraded; this is a stability risk specific to multi-botanical powders. Published data for this specific product in injectable form is limited, so development batches must include filter capacity and endotoxin-reduction data.

For solutions intended for oral use, the powder should be extracted or dissolved in purified water at a controlled temperature. The pH should be adjusted after the addition of the powder, not before, because the botanical acid-base buffering capacity may shift the final pH. If the solution is exposed to air for extended periods, oxidation of polyphenols may produce darkening; a nitrogen overlay or closed vessel is therefore useful. The solution should be filtered through a 10 µm clarifying filter before storage or further dilution in premix operations. These steps reduce the risk of nozzle clogging in metering pumps. For injectables, the solution must also meet the particulate matter count specified by Ph. Eur. 2.9.19; a final membrane filter of 0.22 µm is standard, but earlier filtration stages may be required to prevent premature blocking.

The Absence of Excipients Does Not Remove Incompatibility Constraints

For liquid and semi-solid oral forms, the powder should not be directly blended with strongly alkaline carriers or with oxidizing surfactants without pre-testing. Botanical polyphenols are sensitive to oxidation at high pH and can form insoluble complexes with iron salts, cationic polymers, and some synthetic preservatives. In tablet and capsule formulations, basic amine excipients may induce color change and moisture uptake; binary compatibility studies should follow ICH Q8(R2) principles. The product also differs from finished granules and premixes because it contains no carrier, preservative, or flavoring system, so its chemical interactions are concentrated rather than buffered by a diluent.

Batch-to-batch variance is a recognized limitation of multi-botanical powders. The raw herb content of flavonoids, triterpenoids, and lignans can shift with harvest season, geographic origin, and drying conditions. The API manufacturer typically blends multiple harvest lots to reduce this variance, but a residual relative standard deviation in marker content may remain. Therefore, the receiving manufacturer should re-standardize the active marker content on a dry-weight basis after every campaign. The release certificate should provide actual values rather than pass/fail statements. If the product is intended for injectable use, a change in the species ratio may change both the endotoxin load and the filter capacity.

Compared with a single-herb Artemisia extract or a single-herb Akebia extract, the two-herb powder provides a fixed botanical ratio rather than a purified single marker. This increases the complexity of the chromatographic fingerprint and makes single-marker assay insufficient for release. Multi-marker quantification by HPLC or UPLC is therefore necessary. The product is also not comparable to a finished granule or premix on the basis of extract ratio alone; species substitution patterns, marker profile, and particle-size distribution are more relevant. Published data for this specific configuration is limited, so the supplier development report and batch certificate should be reviewed before substituting this API for a crude powder or a single-herb extract.